Hamamatsu Photonics has completed the acquisition of NKT Photonics, enhancing their technology portfolio in light sources, lasers, and detectors to drive growth in semiconductor, quantum, and medical fields.

Fusion Pharmaceuticals (NASDAQ:FUSN) will be acquired by AstraZeneca (NASDAQ:AZN) for $21/share upfront and $3/share later, with a $2B merger closing in Q2.

Anglo American has initiated a formal process to sell its coal assets and explore options for its nickel operations to thwart BHP's takeover threat and stay independent, according to CEO Duncan Wanblad.

Fusion Pharmaceuticals shareholders have overwhelmingly approved its ~$2B acquisition by AstraZeneca, expected to close by the end of Q2.